Skip to main content
Equibles
SNDX logo

SNDX · Syndax Pharmaceuticals Inc · Metrics

Track SNDX — free

Use SNDX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SNDX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$18.80 +0.57 (+3.10%) At close · Sep 30
Russell 2000 member Rebalance outlook locked
Market Cap
$1.63B
Shares
89.30M
Volume · Sep 30 1.73M Avg daily vol (3M) 1.61M

SNDX metrics

65 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$18.80
Market cap
$1.63B

Price action

20 metrics
Price change (1W)
+0.3%
Price change (30D)
-5.5%
Price change (3M)
-16.6%
Price change (6M)
-21.9%
Price change (YTD)
-13.2%
Price change (1Y)
+17.2%
Trailing year
Price change (5Y)
-6.8%
52-week high
$25.15
52-week low
$13.11
Change from 52-week high
-27.5%
Change from 52-week low
+39.1%
Annualized volatility
50.7%
Annualized volatility (3M)
44.9%
Beta
0.7
RSI (14D)
44.8
Price vs SMA 50
-6.5%
Price vs SMA 200
-12.8%
Avg volume (3M)
1.62M
Relative volume
0.9
Average dollar volume
$32.82M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
89.30M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
5.6×
reciprocal yield 17.7%
EV / EBITDA
—
EV / EBIT
—
P / sales
6.4×
reciprocal yield 15.5%
P / book
107.6
reciprocal yield 0.9%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-13.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-04

Profitability

9 metrics
Gross margin
—
Operating margin
-77.1%
Trailing 12 months
Net margin
-87.6%
Gross profit (TTM)
—
Operating profit (TTM)
−$194.17M
Net income (TTM)
−$220.76M
Trailing 12 months
Diluted EPS (TTM)
$-2.51
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
$-2.72
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.74

Growth

11 metrics
Revenue growth YoY
+91.8%
Year over year
Net income growth YoY
—
Revenue (TTM)
$252.00M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+3.1%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
+157.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-1,462.1%
Return on assets
-31.4%
Debt / equity
22.8
Current ratio
6.8
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
6.4
Interest coverage
-97,085.5
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$203.83M
Latest balance sheet
Cash & equivalents
$336.48M
Total assets
$703.65M
Total debt
$344.03M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$220.64M
Capital expenditures (TTM)
$187,000
R&D (TTM)
$261.80M
SG&A (TTM)
—
Stock compensation (TTM)
$49.40M
R&D / revenue
103.9%
Stock compensation / revenue
19.6%

Ownership (13F)

3 metrics
13F filers
243
13F filer change QoQ
-5
Institutional ownership
121.7%

Short interest

3 metrics
Short interest
23.1%
Latest settlement · 14.7 days to cover
Days to cover
14.7d
Short-squeeze score
76 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$784,776
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1395937 CUSIP 87164F105 13F (30d) 7 filings 7 filers Visit website Investor relations